Loading…
Loading…
LPTX (Leap Therapeutics, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
LPTX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for LPTX and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for LPTX and 80,000+ other tickers.
See exactly how LPTX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LPTX and 80,000+ other tickers.
Leap Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing treatments for various cancers. At the forefront of its pipeline is DKN-01, a monoclonal antibody designed to block Dickkopf-related protein 1 (DKK1). This investigational therapy is currently undergoing several clinical trials, targeting a range of malignancies such as esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics has also forged an option and licensing partnership with BeiGene, Ltd., granting them rights to develop and market DKN-01 across Asia (excluding Japan)…
Leap Therapeutics (NASDAQ: LPTX - Get Free Report) and Panbela Therapeutics (OTCMKTS:PBLA - Get Free Report) are both small-cap manufacturing companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability. Volatility and Risk Leap Therapeutics has a
Nemus Bioscience (OTCMKTS:NMUS - Get Free Report) and Leap Therapeutics (NASDAQ: LPTX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, earnings, dividends and risk. Profitability This table compares Nemus Bioscience and
UCB (OTCMKTS:UCBJF - Get Free Report) and Leap Therapeutics (NASDAQ: LPTX - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk. Insider and Institutional Ownership 30.5% of Leap Therapeutics shares
Leap Therapeutics (NASDAQ: LPTX - Get Free Report) and Vincerx Pharma (NASDAQ: VINC - Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends. Valuation and Earnings This table compares Leap
Leap Therapeutics (NASDAQ: LPTX - Get Free Report) and PaxMedica (NASDAQ: PXMD - Get Free Report) are both small-cap manufacturing companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Insider and Institutional Ownership 30.5% of Leap Therapeutics